ASCO: With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer—FDA panel to review psychedelic drug MDMA for first time — Abbott’s OTC glucose monitor ‘will grow the market’—http://bit.ly/w28kSd #asco2024 #oncology #cancer #bristolmyerssquibb #livercancer #mdma #fda #abbottlabs #cgm #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

ASCO: AstraZeneca's Tagrisso, Imfinzi break new ground in lung cancer—with one standing ovation—Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up — Eli Lilly adds ALS drug prospect with QurAlis deal--http://bit.ly/w28kSd #asco2024 #oncology #cancer #astrazeneca #moderna #elililly #als #lungcancer #merck #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

ASCO24 preview: A look at some of the cancer meeting’s hottest abstracts—Novartis study points to larger role for targeted leukemia drug — Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data--http://bit.ly/w28kSd #asco2024 #oncology #cancer #novartis #leukemia #clinicaltrials #pfizer #lungcancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

ASCO 2024 abstracts released—Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial —Bicycle Therapeutics scores $555M investment for disease prevention --http://bit.ly/w28kSd #asco2024 #asco #ozempic #kidneydisease #novonordisk #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma